Last quarter (Q4 2023), Theriva Biologics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Theriva Biologics's net income was $-5.45M. See Theriva Biologics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 21.43M	$ 21.43M	$ 21.58M	$ -14.27M	$ 10.16M	$ 15.66M
Operating Income	$ -21.43M	$ -21.43M	$ -21.58M	$ -14.27M	$ -10.16M	$ -15.66M
Net Non Operating Interest Income Expense	$ 1.44M	$ 1.44M	$ 512.00K	$ 6.00K	$ 44.00K	$ 283.00K
Other Income Expense	$ -660.00K	$ -660.00K	$ 1.62M	-	-	-
Pretax Income	$ -19.99M	$ -19.99M	$ -21.11M	$ -14.27M	$ -10.12M	$ -15.38M
Tax Provision	$ -1.64M	$ -1.64M	$ -1.43M	$ -932.00K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -18.33M	$ -18.35M	$ -20.02M	$ -23.19M	$ -12.56M	$ -16.08M
Basic EPS	$ -1.15	$ -1.14	$ -1.31	$ -0.19	$ -0.66	$ -0.98
Diluted EPS	$ -1.15	$ -1.14	$ -1.31	$ -0.19	$ -0.66	$ -0.98
Basic Average Shares	$ 64.43M	$ 16.11M	$ 15.33M	$ 121.88M	$ 19.01M	$ 16.44M
Diluted Average Shares	$ 64.43M	$ 16.11M	$ 15.33M	$ 121.88M	$ 19.01M	$ 16.44M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 21.43M	$ 21.43M	$ 21.58M	$ -14.27M	$ 10.16M	$ 15.66M
Net Income From Continuing And Discontinued Operation	$ -18.33M	$ -18.35M	$ -19.68M	$ -14.27M	$ -10.04M	$ -15.30M
Normalized Income	$ -11.35M	$ -22.29M	-	-	$ -10.04M	$ -15.30M
Interest Expense	-	-	-	-	-	-
EBIT	$ -20.35M	$ -19.99M	$ -21.11M	$ -14.27M	$ -10.16M	$ -15.66M
EBITDA	$ -20.22M	$ -19.85M	$ -21.02M	$ -14.19M	$ -9.96M	$ -15.42M

Currency in USD

Theriva Biologics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing